Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.43 |
| ▸ | ACE | P12821 | 3/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 15/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 15/20 | 0.43 |
| ▸ | FNTA | P49354 | 1/20 | 0.33 |
| ▸ | FNTB | P49356 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7384406 | 0.94 | ACE2 (0.54) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL1656651 | 0.92 | CYP11B1 (0.52) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL7429445 | 0.91 | ACE2 (0.43) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL7382597 | 0.91 | CYP11B1 (0.53) | ACE2ACECYP11B1CYP11B2 | |
| SCHEMBL7391521 | 0.91 | ACE2 (0.45) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL7382789 | 0.90 | ACE2 (0.46) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL3712509 | 0.89 | ACE2 (0.41) | ACE2ACECYP11B1CYP11B2 | |
| SCHEMBL3712452 | 0.89 | ACE2 (0.41) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL1661113 | 0.88 | CYP11B1 (0.41) | ACE2ACECYP11B1CYP11B2FNTA | |
| SCHEMBL3704205 | 0.88 | CYP11B1 (0.42) | ACE2ACECYP11B1CYP11B2FNTA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2010093804-A1 | ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICALS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| EP-2059234-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | Ore Pharmaceuticals Inc. (US) | 2009-05-20 | — | — | EP | disclosed |
| WO-2008031014-A1 | METHOD FOR REDUCING OR ALLEVIATING INFLAMMATION IN THE DIGESTIVE TRACT | ORE PHARMACEUTICALS INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| WO-2000066104-A9 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1183019-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000066104-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |